Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,043 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS.
Yoshitake Y, Fukuma D, Yuno A, Hirayama M, Nakayama H, Tanaka T, Nagata M, Takamune Y, Kawahara K, Nakagawa Y, Yoshida R, Hirosue A, Ogi H, Hiraki A, Jono H, Hamada A, Yoshida K, Nishimura Y, Nakamura Y, Shinohara M. Yoshitake Y, et al. Among authors: nishimura y. Clin Cancer Res. 2015 Jan 15;21(2):312-21. doi: 10.1158/1078-0432.CCR-14-0202. Epub 2014 Nov 12. Clin Cancer Res. 2015. PMID: 25391695 Clinical Trial.
Head and neck cancer antigens recognized by the humoral immune system.
Monji M, Senju S, Nakatsura T, Yamada K, Sawatsubashi M, Inokuchi A, Nishimura Y. Monji M, et al. Among authors: nishimura y. Biochem Biophys Res Commun. 2002 Jun 14;294(3):734-41. doi: 10.1016/S0006-291X(02)00543-0. Biochem Biophys Res Commun. 2002. PMID: 12056832
Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker.
Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, Hosaka S, Beppu T, Ishiko T, Kamohara H, Ashihara H, Katagiri T, Furukawa Y, Fujiyama S, Ogawa M, Nakamura Y, Nishimura Y. Nakatsura T, et al. Among authors: nishimura y. Biochem Biophys Res Commun. 2003 Jun 20;306(1):16-25. doi: 10.1016/s0006-291x(03)00908-2. Biochem Biophys Res Commun. 2003. PMID: 12788060
Proliferation potential-related protein, an ideal esophageal cancer antigen for immunotherapy, identified using complementary DNA microarray analysis.
Yoshitake Y, Nakatsura T, Monji M, Senju S, Matsuyoshi H, Tsukamoto H, Hosaka S, Komori H, Fukuma D, Ikuta Y, Katagiri T, Furukawa Y, Ito H, Shinohara M, Nakamura Y, Nishimura Y. Yoshitake Y, et al. Among authors: nishimura y. Clin Cancer Res. 2004 Oct 1;10(19):6437-48. doi: 10.1158/1078-0432.CCR-04-0841. Clin Cancer Res. 2004. PMID: 15475430
Identification of glypican-3 as a novel tumor marker for melanoma.
Nakatsura T, Kageshita T, Ito S, Wakamatsu K, Monji M, Ikuta Y, Senju S, Ono T, Nishimura Y. Nakatsura T, et al. Among authors: nishimura y. Clin Cancer Res. 2004 Oct 1;10(19):6612-21. doi: 10.1158/1078-0432.CCR-04-0348. Clin Cancer Res. 2004. PMID: 15475451
[New era of tumor immunotherapy].
Yoshitake Y, Nakatsura T, Nishimura Y. Yoshitake Y, et al. Among authors: nishimura y. Nihon Rinsho. 2005 Apr;63 Suppl 4:46-55. Nihon Rinsho. 2005. PMID: 15861634 Review. Japanese. No abstract available.
4,043 results